ArticleNeuroImage. Clinical2019
Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity.
Article in NeuroImage. Clinical, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non-Hispanic White cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Pooled it
- Association of residential neighborhood disadvantage with amyloid PET positivity among cognitively impaired individuals.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2026Article
- Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans.The journal of prevention of Alzheimer's disease · 2026Article
- Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology.Neurology. Clinical practice · 2025Article
- Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Predictors of Retention in the 1Florida Alzheimer's Disease Research Center (ADRC) Over Two Waves.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2025Article
- Discussing the Interplay of Social Determinants of Health, Aging, and Alzheimer's Biomarkers in U.S. Latinos.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Review
- Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition.Ageing research reviews · 2024Review
- Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Sex significantly predicts medial temporal volume when controlling for the influence of ApoE4 biomarker and demographic variables: A cross-ethnic comparison.Journal of the International Neuropsychological Society : JINS · 2024Article
- Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.Frontiers in neurology · 2024Article
- Retinal vascular changes are associated with PET-based biomarkers of Alzheimer's disease: A pilot study.Journal of Alzheimer's disease reports · 2024Article
- Different aspects of failing to recover from proactive semantic interference predicts rate of progression from amnestic mild cognitive impairment to dementia.Frontiers in aging neuroscience · 2024Article
- Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.medRxiv : the preprint server for health sciences · 2023Article
- Comparison of genetic and health risk factors for mild cognitive impairment and Alzheimer's disease between Hispanic and non-Hispanic white participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- A unique color-coded visualization system with multimodal information fusion and deep learning in a longitudinal study of Alzheimer's disease.Artificial intelligence in medicine · 2023Article
- Semantic intrusion errors are associated with plasma Ptau-181 among persons with amnestic mild cognitive impairment who are amyloid positive.Frontiers in neurology · 2023Article
- APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.European journal of nuclear medicine and molecular imaging · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
Abstract
The threshold for amyloid positivity by visual assessment on PET has been validated by comparison to amyloid load measured histopathologically and biochemically at post mortem. As such, it is now feasible to use qualitative visual assessment of amyloid positivity as an in-vivo gold standard to determine those factors which can modify the quantitative threshold for amyloid positivity. We calculated quantitative amyloid load, measured as Standardized Uptake Value Ratios (SUVRs) using [18-F]florbetaben PET scans, for 159 Hispanic and non-Hispanic participants, who had been classified clinically as Cognitively Normal (CN), Mild Cognitive Impairment (MCI) or Dementia (DEM). PET scans were visually rated as amyloid positive (A+) or negative (A-), and these judgments were used as the gold standard with which to determine (using ROC analyses) the SUVR threshold for amyloid positivity considering factors such as age, ethnicity (Hispanic versus non-Hispanic), gender, cognitive status, and apolipoprotein E ε4 carrier status. Visually rated scans were A+ for 11% of CN, 39.0% of MCI and 70% of DEM participants. The optimal SUVR threshold for A+ among all participants was 1.42 (sensitivity = 94%; specificity = 92.5%), but this quantitative threshold was higher among E4 carriers (SUVR = 1.52) than non-carriers (SUVR = 1.31). While mean SUVRs did not differ between Hispanic and non-Hispanic participants;, a statistically significant interaction term indicated that the effect of E4 carrier status on amyloid load was greater among non-Hispanics than Hispanics. Visual assessment, as the gold standard for A+, facilitates determination of the effects of various factors on quantitative thresholds for amyloid positivity. A continuous relationship was found between amyloid load and global cognitive scores, suggesting that any calculated threshold for the whole group, or a subgroup, is artefactual and that the lowest calculated threshold may be optimal for the purposes of early diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.